Canada markets open in 56 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8824+0.0524 (+6.31%)
At close: 04:00PM EDT
0.8825 +0.00 (+0.01%)
Pre-Market: 08:33AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8300
Open0.8520
Bid0.8824 x 3200
Ask0.8940 x 900
Day's Range0.8400 - 0.8979
52 Week Range0.8300 - 3.4800
Volume4,224,213
Avg. Volume6,999,470
Market Cap199.791M
Beta (5Y Monthly)3.79
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

    U.S. Food & Drug Administration (FDA) approves enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with CEP290 gene mutationsOcugen has completed enrollment of adult RP patients with NR2E3 and RHO mutations in the Phase 1/2 trial and expanded enrollment in LCA patients with CEP290 mutations MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnolo

  • GlobeNewswire

    Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

    MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, Cal

  • GlobeNewswire

    Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

    MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer. “Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching our c